The Response of Biologic Prices to Biosimilar Entry: Case Studies of Genotropin and Humira

Biologics are a class of drugs with complex molecules that generally come from living organisms (ex: bacteria, yeast, animal cells), which is what makes them very difficult and expensive to obtain (https://www.fda.gov/drugs/biosimilars/overview-health-care-professionals). According to the IQVIA Institute for Human Data Science’s The Use of Medicines in the U.S. 2024 report, biologics only made up 5% of prescribed drugs in the US, yet contributed to more than 50% of the country's total prescription drug spending (Aitken et al., 2024). To avoid these extreme costs, patients may instead opt for a biosimilar, a kind of biologic drug that is highly similar to an existing biologic. These biosimilars can only be developed and sold after the patent for the original biologic expires, and are on average 60% cheaper than their original biologic (https://www.who.int/news/item/13-02-2025-biosimilars--expanding-access-to-essential-biologic-therapies). Crucially, substituting biologics for cheaper biosimilars helps those in need gain access to important medicines. Within the next decade, 118 biosimilars are expected to lose their patent protections, allowing hundreds of new biosimilar medicines to enter pharmaceutical markets (Aitken et al., 2025). It is currently vital to fully understand how they impact biologic prices.
This paper hopes to identify the real effect of patent protection loss on biologic markets. Biosimilar introduction is expected to drive down biologic prices since when competition is introduced, manufacturers should lower prices in order to remain relevant in their markets. Therefore, the hypothesis is that biosimilar entry drives biologic prices down. In reality, however, executive decision making is influenced by factors such as market monopolies and individual ideals, rendering theoretical predictions imprecise. This paper examines the real-world impact through the case studies of Genotropin and Humira, two widely used biologics, as biosimilars entered their respective markets. The prices of the biologics were observed over time, considering an intervention point of biosimilar entry. Determining prices is beneficial for understanding markets, as it reflects the market equilibrium (Banton, 2025). Price trends were examined using Medicaid’s State Drug Utilization Data, and the National Average Drug Acquisition Cost, respectively. This allowed for reliable comparison over time, an approach made necessary by the limited availability of continuous pricing data for most biologic drugs across both databases.

NA

1. Aitken, M., Bhardwaj, T., & Pritchett, J. (2025, February). Assessing the Biosimilar Void in the U.S. Https://Www.iqvia.com/Insights/The-Iqvia-Institute/Reports-And-Publications/Reports/Assessing-The-Biosimilar-Void-In-The-Us. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/assessing-the-biosimilar-void-in-the-us [Google Scholar] [Crossref]

2. Aitken, M., Kleinrock, M., & Pritchett, J. (2024, April). The Use of Medicines in the U.S. 2024: Usage and Spending Trends and Outlook to 2028. Https://Www.iqvia.com/Insights/The-Iqvia-Institute/Reports-And-Publications/Reports/The-Use-of-Medicines-In-The-Us-2024. https://www.investopedia.com/terms/t/theory-of-price.asp [Google Scholar] [Crossref]

3. Banton, C. (2025, October 7). Understanding the Theory of Price: Supply, Demand, and Market Equilibrium. Investopedia. https://www.investopedia.com/terms/t/theory-of-price.asp [Google Scholar] [Crossref]

4. Biosimilars: expanding access to essential biologic therapies. (2025, February 13). Who.int; World Health Organization: WHO. https://www.who.int/news/item/13-02-2025-biosimilars--expanding-access-to-essential-biologic-therapies [Google Scholar] [Crossref]

5. Collier, R. (2013). Drug patents: the evergreening problem. Canadian Medical Association Journal, 185(9), E385–E386. https://doi.org/10.1503/cmaj.109-4466 competition. (2025). Oxford Reference. https://www.oxfordreference.com/display/10.1093/oi/authority.20110803095628957 [Google Scholar] [Crossref]

6. Constantino, A. K., & Capoot, A. (2024, May 1). Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors. CNBC. https://www.cnbc.com/2024/05/01/healthy-returns-humira-sales-are-falling-but-abbvie-has-successors.html [Google Scholar] [Crossref]

7. Contreras, B. (2023, February 8). It’s Unlikely that Humira Biosimilars Will Drive Down Drug Costs. Dermatologytimes.com; Dermatology Times. https://www.dermatologytimes.com/view/it-s-unlikely-that-humira-biosimilars-will-drive-down-drug-costs [Google Scholar] [Crossref]

8. Cristian, R. (2025, June 29). Monopoly and Monopolistic Competition: Market Power. Economics.MBA | Micro, Macro, Models and Economics Theories - Learn Economics with Clear Explanations in Microeconomics, Macroeconomics and Theories. Ideal for Online Learning, Studies and Exam Prep. https://economics.mba/economists/monopoly-and-monopolistic-competition-a-deep-dive-into-market-power/ [Google Scholar] [Crossref]

9. Devale, D. (2025, July 7). Biologics Market Size, Share, Growth, Report 2025 to 2034. Cervicornconsulting.com. https://www.cervicornconsulting.com/biologics-market [Google Scholar] [Crossref]

10. Dolan, R., & Tian, M. (2020). Pricing and Payment for Medicaid Prescription Drugs. In Henry J Kaiser Family Foundation (pp. 1–14). https://files.kff.org/attachment/Issue-Brief-Pricing-and-Payment-for-Medicaid-Prescription-Drugs [Google Scholar] [Crossref]

11. Ellison, G., & Ellison, S. F. (2011). Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration. American Economic Journal Microeconomics, 3(1), 1–36. https://doi.org/10.1257/mic.3.1.1 [Google Scholar] [Crossref]

12. Grabowski, H. G., Guha, R., & Salgado, M. (2014). Regulatory And Cost Barriers Are Likely to Limit Biosimilar Development and Expected Savings in The Near Future. Health Affairs, 33(6), 1048–1057. https://doi.org/10.1377/hlthaff.2013.0862 [Google Scholar] [Crossref]

13. Medh, K. (2023, June 16). From Triumph to Competition: Humira’s Journey and the Rise of Biosimilars. ZOOMRX. https://blog.zoomrx.com/launch-excellence/from-triumph-to-competition-humiras-journey-and-the-rise-of-biosimilars/ [Google Scholar] [Crossref]

14. Myers, & Stauffer, L. (2021). NATIONAL AVERAGE DRUG ACQUISITION COST (NADAC) DATA FIELD DEFINITIONS (pp. 1–2). https://www.medicaid.gov/media/25376 [Google Scholar] [Crossref]

15. National Average Drug Acquisition Cost | Medicaid. (n.d.). Medicaid.gov. Retrieved November 30, 2025, from https://www.medicaid.gov/medicaid/nadac [Google Scholar] [Crossref]

16. Overview for Health Care Professionals. (2024, August 1). U.S. Food and Drug Administration. https://www.fda.gov/drugs/biosimilars/overview-health-care-professionals [Google Scholar] [Crossref]

17. Pinder, J. (2023, July 24). How much does Humira cost? A deep dive on a big drug moneymaker. ClearHealthCosts. https://clearhealthcosts.com/blog/2023/07/how-much-does-humira-cost-a-deep-dive-on-a-big-drug-moneymaker/ [Google Scholar] [Crossref]

18. Pope, C. (Ed.). (2025, June 4). Humira: Uses, Dosage, Side Effects, Warnings. Drugs.com. https://www.drugs.com/humira.html [Google Scholar] [Crossref]

19. Puckey, M. (Ed.). (2025, September 3). Genotropin: Uses, Dosage, Side Effects, Warnings. Drugs.com. https://www.drugs.com/genotropin.html [Google Scholar] [Crossref]

20. Purgato M., & Barbui C. (2012). What is the WHO essential medicines list? Epidemiology and Psychiatric Sciences, 21(4), 343–345. https://doi.org/10.1017/s204579601200039x [Google Scholar] [Crossref]

21. Raju, Ajay. (2025, August 4). The $400 Billion Patent Cliff: Big Pharma’s Revenue Crisis. The American Bazaar. https://americanbazaaronline.com/2025/08/04/the-400-billion-patent-cliff-big-pharmas-revenue-crisis-465788/ [Google Scholar] [Crossref]

22. Rashid, A. (2025, July 24). Top 50 Best-Selling Drugs to Watch in 2025: Insights from 2024 Sales Data. Xtalks. https://xtalks.com/top-50-best-selling-drugs-to-watch-in-2025-insights-from-2024-sales-data-4343/ [Google Scholar] [Crossref]

23. Righetti, N. (2021). Chapter10 Intervention Analysis | Time Series Analysis With R. Github.io. https://nicolarighetti.github.io/Time-Series-Analysis-With-R/intervention-analysis.html [Google Scholar] [Crossref]

24. Rind, D. M., Agboola, F., & Nikitin, D. (2023, December 11). ICER Identifies Most Significant 2022 US Drug-Price Hikes Unsupported by New Clinical Evidence - ICER. ICER. https://icer.org/news-insights/press-releases/icer-identifies-most-significant-2022-us-drug-price-hikes-unsupported-by-new-clinical-evidence [Google Scholar] [Crossref]

25. Robbins, R. (2023, January 28). How a Drug Company Made $114 Billion by Gaming the U.S. Patent System. Nytimes.com; The New York Times. https://www.nytimes.com/2023/01/28/business/humira-abbvie-monopoly.html# [Google Scholar] [Crossref]

26. State Drug Utilization Data | Medicaid. (2025, January 13). Medicaid.gov. https://www.medicaid.gov/medicaid/prescription-drugs/state-drug-utilization-data [Google Scholar] [Crossref]

27. Thornton, P. (Ed.). (2025, March 26). Omnitrope Pen: Uses, Warnings, Avoid, Interactions. Drugs.com. https://www.drugs.com/omnitrope.html [Google Scholar] [Crossref]

28. Winegarden, W. (2024, October 1). Biosimilars Often Reduce Prices by 50 Percent or More - Center for Medical Economics and Innovation. Center for Medical Economics and Innovation. https://medecon.org/biosimilars-often-reduce-prices-by-50-percent-or-more/ [Google Scholar] [Crossref]

• Problem-Based Learning Strategy: Effect on Achievement of Genetics among Biology Students in Colleges of Education Oyo, Oyo State
• Gut Content Analysis of Siganus canaliculatus (Danggit)
• Predicting Human Neurotherapeutic Response through Preclinical Imaging Intelligence
• Can Algicidal Bacteria be the Solution to Successfully Manage Freshwater Algal Blooms?
• Boosting Carbon Capture: Progress in Enhancing RuBisCO’s Carboxylase Activity